HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

Por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dent, Paul
Publicado no Oncotarget (2017)

The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury

Por Liu, Liying, Lalani, Alshad, Dai, Erbin, Seet, Bruce, Macauley, Colin, Singh, Raj, Fan, Lilly, McFadden, Grant, Lucas, Alexandra
Publicado em 2000

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells

Por Booth, Laurence, Roberts, Jane L., Samuel, Peter, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2018)

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration

Por Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Kirkwood, John, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
Publicado no Oncotarget (2017)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

Por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Kirkwood, John, Sander, Cindy, Avogadri-Connors, Francesca, Cutler Jr, Richard E., Lalani, Alshad S., Dent, Paul
Publicado no Cancer Biol Ther (2017)

Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts

Por Miles, Kiersten Marie, Seshadri, Mukund, Ciamporcero, Eric, Adelaiye, Remi, Gillard, Bryan, Sotomayor, Paula, Attwood, Kristopher, Shen, Li, Conroy, Dylan, Kuhnert, Frank, Lalani, Alshad S., Thurston, Gavin, Pili, Roberto
Publicado no PLoS One (2014)

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

Por Ribas, Ricardo, Pancholi, Sunil, Rani, Aradhana, Schuster, Eugene, Guest, Stephanie K., Nikitorowicz-Buniak, Joanna, Simigdala, Nikiana, Thornhill, Allan, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dowsett, Mitch, Johnston, Stephen R., Martin, Lesley-Ann
Publicado no Breast Cancer Res (2018)

An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Por Hanker, Ariella B., Brewer, Monica Red, Sheehan, Jonathan H., Koch, James P., Sliwoski, Gregory R., Nagy, Rebecca, Lanman, Richard, Berger, Michael F., Hyman, David M., Solit, David B., He, Jie, Miller, Vincent, Cutler, Richard E., Lalani, Alshad S., Cross, Darren, Lovly, Christine M., Meiler, Jens, Arteaga, Carlos L.
Publicado no Cancer Discov (2017)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Por Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, Solit, David B.
Publicado no Nature (2018)